241 DNA and RNA alterations associated with colorectal peritoneal metastases: A systematic review Table 1. Continued Reference Year Country Study Design Patient Inclusion Period Reasons for Patient Exclusion No. of Subjects No. of Genes Investigated Aim of the Study Start End Yang et al. 50 2021 China CH 01/2015 03/2020 Chemo- or radiotherapy before NGS and no follow- up information. 582 1 To evaluate the frequency and phenotypic characteristics of mCRC with somatic RET mutation. Yokota et al. 40 2011 Japan CH 2002 2010 - 229 2 To investigate the clinicopathological features and prognostic impact of KRAS/BRAF mutation in advanced and recurrent CRC patients. Zihui Yong et al. 51 2018 Singapore CH 01/2010 12/2014 Appendiceal tumors, other stages than stage 4 and patients without metastases. 363 1 To describe the metastatic pattern of advanced CRC by assessing the interaction between the KRAS mutational status and the location of primary tumors. CC, case control study; CH, cohort study; CRC, colorectal cancer; CRS, cytoreductive surgery; FAP, familiarly adenomatous polyposis; HNPCC, hereditary non-polyposis colon cancer; HIPEC, hyperthermic intraperitoneal chemotherapy; MCH, matched cohort study; mCRC, metastatic colorectal cancer; PM, peritoneal metastases. 11
RkJQdWJsaXNoZXIy MTk4NDMw